Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

Misfolded neuronal proteins have been identified in a number of neurodegenerative disorders and have been implicated in the pathogenesis of diseases that include Alzheimer's disease, Parkinson's disease, prion-based dementia, Huntington's disease (HD), and other polyglutamine diseases. Although underlying mechanisms remain the subject of ongoing research, it is clear that aberrant processing, protein degradation, and aggregate formation or spurious protein association of the abnormal neuronal proteins may be critical factors in disease progression. Recent work in these diseases has demonstrated in vitro that specific engineered antibody species, peptides, or other general agents may suppress the formation of aggregates. We have modified an approach with intracellularly expressed single-chain Fv (sFv) antibodies (intrabodies) that bind with unique HD protein epitopes. In cell and tissue culture models of HD, anti-N-terminal huntingtin intrabodies (C4 sFv) reduce aggregation and cellular toxicity. Here, we present the crucial experiment of intrabody-mediated in vivo suppression of neuropathology, using a Drosophila model of HD. In the presence of the C4 sFv intrabody, the proportion of HD flies surviving to adulthood increases from 23% to 100%, and the mean and maximum lifespan of adult HD flies is significantly prolonged. Neurodegeneration and formation of visible huntingtin aggregates are slowed. We conclude from this investigation that engineered intrabodies are a potential new class of therapeutic agents for the treatment of neurodegenerative diseases. They may also serve as tools for drug discovery and validation of sites on mutant neuronal proteins that could be exploited for rational drug design.

[1]  M. MacDonald,et al.  A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's disease , 2005, Neurobiology of Disease.

[2]  Ann-Shyn Chiang,et al.  Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  David W. Colby,et al.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Sierks,et al.  A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed α-synuclein , 2004 .

[5]  H. Voss,et al.  Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. , 2004, Human gene therapy.

[6]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[7]  R. Mandel,et al.  Clinical trials in neurological disorders using AAV vectors: promises and challenges. , 2004, Current opinion in molecular therapeutics.

[8]  K Dane Wittrup,et al.  Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. , 2004, Journal of molecular biology.

[9]  T. Rabbitts,et al.  Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. , 2004, Current molecular medicine.

[10]  G. Bates,et al.  Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. , 2004, Human molecular genetics.

[11]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[12]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[13]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[14]  J. Marsh,et al.  Can flies help humans treat neurodegenerative diseases? , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  M. Beal,et al.  Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.

[16]  R. Wetzel,et al.  Inhibition of polyglutamine aggregate cytotoxicity by a structure‐based elongation inhibitor , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  J. Littleton,et al.  Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Bin Yuan,et al.  Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments† , 2004 .

[19]  R. Murphy,et al.  A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. , 2004, Brain research. Molecular brain research.

[20]  Nancy M Bonini,et al.  Human neurodegenerative disease modeling using Drosophila. , 2003, Annual review of neuroscience.

[21]  Leslie Michels Thompson,et al.  A Rapid Cellular FRET Assay of Polyglutamine Aggregation Identifies a Novel Inhibitor , 2003, Neuron.

[22]  Richard G. Brusch,et al.  Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic PolyQ Proteins in Drosophila , 2003, Neuron.

[23]  D. Sane,et al.  Intrabody and intrakine strategies for molecular therapy. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  W. Strittmatter,et al.  Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. , 2003, Human molecular genetics.

[25]  James E Bear,et al.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[27]  Ari Helenius,et al.  Quality control in the endoplasmic reticulum , 2003, Nature Reviews Molecular Cell Biology.

[28]  Beate Gerstbrein,et al.  Dying for a cause: invertebrate genetics takes on human neurodegeneration , 2003, Nature Reviews Genetics.

[29]  Leslie M Thompson,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Steven Wiley,et al.  Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library , 2003, Nature Biotechnology.

[31]  Junying Yuan,et al.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders , 2003, Nature.

[32]  Christopher A. Ross,et al.  Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization* , 2002, The Journal of Biological Chemistry.

[33]  H. Zoghbi,et al.  Mouse and fly models of neurodegeneration. , 2002, Trends in genetics : TIG.

[34]  T. Tabata,et al.  Androgen-Dependent Neurodegeneration by Polyglutamine-Expanded Human Androgen Receptor in Drosophila , 2002, Neuron.

[35]  D. Rubinsztein.  Lessons from animal models of Huntington's disease. , 2002, Trends in genetics : TIG.

[36]  D. Housman,et al.  A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila , 2002, Nature Genetics.

[37]  P. Patterson,et al.  Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[39]  D. Housman,et al.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. Zoghbi,et al.  Identification of genes that modify ataxin-1-induced neurodegeneration , 2000, Nature.

[41]  Martin R. Johnson,et al.  A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  S. Benzer,et al.  Genetic suppression of polyglutamine toxicity in Drosophila. , 2000, Science.

[43]  H. Paulson,et al.  Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.

[44]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[45]  Iris Salecker,et al.  Polyglutamine-Expanded Human Huntingtin Transgenes Induce Degeneration of Drosophila Photoreceptor Neurons , 1998, Neuron.

[46]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[47]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[48]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[49]  N. Perrimon,et al.  Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. , 1993, Development.

[50]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[51]  W. T. Catton.  Information processing in the visual systems of arthropods , 1974 .

[52]  K. N. Leibovic,et al.  Information Processing in the Visual Systems of Arthropods , 1974 .

[53]  F. Newell.  Information Processing in the Visual Systems of Arthropods , 1973 .

[54]  R. Murphy,et al.  Gene transfer methods for CNS organotypic cultures: a comparison of three nonviral methods. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  H. Theisen,et al.  Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. , 2000, Human molecular genetics.

[56]  A. Cossins,et al.  Responses of the Na+/H+ exchanger of European flounder red blood cells to hypertonic, beta-adrenergic and acidotic stimuli. , 1999, The Journal of experimental biology.

[57]  E. Haber,et al.  Antibody binding sites. , 1996, Advances in protein chemistry.